Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
FPLLA-PETHEMA-001: Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
1 other identifier
observational
30
1 country
28
Brief Summary
Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central \[CNS\], bone marrow \[MO\], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2018
Longer than P75 for all trials
28 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 15, 2018
CompletedFirst Submitted
Initial submission to the registry
June 18, 2018
CompletedFirst Posted
Study publicly available on registry
June 28, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2022
CompletedFebruary 1, 2022
January 1, 2022
4.5 years
June 18, 2018
January 31, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Description pronostic factors
Study of the main clinical-biological variables as independent risk factors in adult patients (\> 15 years) diagnosed with ALL
1 year
Secondary Outcomes (2)
overall survival
1 year
Progression free survival
1 year
Eligibility Criteria
Patients\> 15 years diagnosed with ALL and treated with the PETHEMA protocols for ALL
You may qualify if:
- Patients \>15 years old diagnosed with ALL and treated with the PETHEMA protocols for ALL
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (28)
Hospital Mútua de Terrassa
Terrassa, Barcelona, Spain
Hospital Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital General de Alicante
Alicante, Spain
H. de la Santa Creu I Sant Pau
Barcelona, Spain
H. Vall d'Hebron, Barcelona
Barcelona, Spain
H.Universitari Germans Trias I Pujol de Badalona
Barcelona, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital de Basurto
Basurto, Spain
ICO-Duran i Reynals
Bellvitge, Spain
Hospital Donostia
Donostia / San Sebastian, Spain
H. Univ. de Girona Dr. Josep Trueta (ICO)
Girona, Spain
Hospital Arnau de Vilanova (Lleida)
Lleida, Spain
Hospital Lucus Augusti
Lugo, Spain
H. Gregorio Marañón
Madrid, Spain
Hospital San Pedro de Alcántara.
Málaga, Spain
Hospital General Universitario Morales Messeguer
Murcia, Spain
Hospital Son Espases
Palma de Mallorca, Spain
Hospital Son Llatzer
Palma de Mallorca, Spain
Complejo Hospitalario de Navarra
Pamplona, Spain
Parc Taulí
Sabadell, Spain
H. Univ. de Salamanca
Salamanca, Spain
C. H. U. de Santiago
Santiago de Compostela, Spain
Complejo Hosp. Regional Virgen del Rocío
Seville, 41013, Spain
Hospital del Valme
Seville, Spain
H. Joan XXIII
Tarragona, Spain
Hoapital La Fe
Valencia, Spain
Hospital Arnau de Vilanova (Valencia)
Valencia, Spain
Hospital Universitari Clínic València
Valencia, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 18, 2018
First Posted
June 28, 2018
Study Start
June 15, 2018
Primary Completion
December 30, 2022
Study Completion
December 30, 2022
Last Updated
February 1, 2022
Record last verified: 2022-01